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Activation of the TGF-/Smad signaling pathway in focal
segmental glomerulosclerosis
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Activation of the TGF-/Smad signaling pathway in focal seg-
mental glomerulosclerosis.
Background. Although the pathogenetic relevance of trans-
forming growth factor- (TGF-) to glomerulosclerosis is well
established, it is not known whether a signal transduction cas-
cade of TGF- is involved in the development of focal segmen-
tal glomerulosclerosis (FSGS), nor is it clear how TGF-1 is
activated during the course of FSGS formation.
Methods. We examined the expression patterns of TGF-1,
thrombospondin-1 (TSP-1), TGF- type II receptor (TGF-IIR),
phosphorylated Smad2/Smad3, and podocyte-specific epitopes
[Wilms’ tumor protein-1 (WT-1) and glomerular epithelial pro-
tein-1 (GLEPP-1)] in 15 renal biopsy specimens with idiopathic
FSGS and six renal biopsies with no detectable abnormalities
by means of immunohistochemistry. The mRNA expression
patterns of TGF-1, TGF-IIR, and TSP-1 were further evalu-
ated by in situ hybridization in seven biopsies.
Results. In the controls, immunostaining for TGF-1, TSP-1,
TGF-IIR, and phosphorylated Smad2/Smad3 was almost neg-
ligible, but an apparent signal for TGF-1, TSP-1, and TGF-IIR
mRNAs was observed in the visceral glomerular epithelial cells
(GEC). In the cases of FSGS, the expression levels of TGF-1,
TSP-1, and TGF-IIR proteins and mRNAs and phosphory-
lated Smad2/Smad3 were significantly increased, particularly in
the GEC of the sclerotic segments, wherein WT-1 and GLEPP-1
were not detected.
Conclusion. These results suggest that damage to podocyes
may stimulate TGF-1, TSP-1, and TGF-IIR expression in
GEC, thereby activating the Smad signaling pathway and, in
so doing, leading to overproduction of the extracellular matrix
(ECM). Thus, a signal transduction cascade of the TGF-/
Smad signaling pathway, which is activated in the GEC, ap-
pears to be involved in the development of FSGS.
Focal segmental glomerulosclerosis (FSGS) constitutes
a pathologic hallmark of progressive glomerular injury
and is characterized by segmental collapse of the glomer-
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ular tuft with the accumulation of extracellular matrix
(ECM). Almost any type of glomerular pathology could
be complicated in its chronic course by the presence of
FSGS lesions, which would not be able to be morphologi-
cally distinguished from primary FSGS [1, 2].
The initial lesion that leads to the development of
FSGS seems to be cellular [3–7], and scar formation gener-
ally follows [7, 8]. The cellular lesion consists of hyper-
plastic glomerular epithelial cells (GEC) overlying the
sclerotic or collapsed glomerular tufts [3, 4]. Injury to
podocytes is the first event to occur in the natural course
of FSGS [3, 4], which may result in the phenotypic dys-
regulation of the podocytes and cell proliferation [7, 9].
Transforming growth factor- (TGF-) is a key regu-
lator of ECM [10, 11]. The fibrogenic actions of TGF-
have been implicated in the development of pathologic
renal fibrosis [11–13]. In the hyperplastic GEC of FSGS
lesions, obtained from cases of IgA nephropathy, the
expression of TGF-1 protein and mRNA was markedly
increased, whereas no significant expression of TGF-1
protein was observed in the mesangial proliferative le-
sions [14]. No study has been done to confirm this in
patients with primary FSGS, although segmental intra-
glomerular staining for TGF-1 has been described in
some reports [13, 15].
TGF- is secreted as an inactive precursor, consisting
of an active peptide associated with a latency-associated
peptide (LAP) [16]. The activation of latent TGF- can
be induced in vitro by the proteolysis of LAP by using
denaturing factors [17]. However, its activation in vivo is
more complex and is not well understood. Some research-
ers have suggested that thrombospondin-1 (TSP-1), an
ECM protein, is a potent physiologic activator of latent
TGF- [18–20]. The interaction of the KRFK sequence
of TSP-1 with the LAP induces the activation of TGF-
[21]. The presence of TSP-1 has been demonstrated in
human crescents [22, 23] and in other early fibrous glo-
merular scars [22]. So far, no study has sought to deter-
mine whether TSP-1 is expressed in the GEC of FSGS
lesions, in association with TGF-.
Activated TGF- binds to three different types of ser-
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ine/threonine kinase receptors [24]. Upon TGF- bind-
ing, the constitutively active TGF- type II receptor
(TGF-IIR) associates with and phosphorylates the type I
receptor [25]. The type I receptor kinase then phosphor-
ylates the Smad2 and Smad3 proteins [26, 27]. The phos-
phorylated Smads form heteromeric complexes with
Smad4. These complexes translocate into the nucleus,
where they modulate the expression of the target genes
[26, 28–32]. Increased expression of the three TGF-
receptors was reported in the lesions of glomerulosclero-
sis and in crescents [33]. In the glomeruli of db/db mice,
a genetic model of type 2 diabetes, increased staining
for TGF-IIR protein [34, 35] and Smad3 [35] has been
described. As yet, the expression patterns of TGF-IIR
and phosphorylated Smads in the lesions of human FSGS
have not been clearly identified.
We hypothesized that damage to podocytes may lead
to their phenotypic dysregulation and, consequently, to
the activation of the TGF-/Smad signaling pathway, cul-
minating in the development of FSGS. Thus, this study
was designed to demonstrate the presence of TGF-/
Smad signaling proteins in the lesions of FSGS, by evaluat-
ing the expression patterns of TGF-, TSP-1, TGF-IIR,
and phosphorylated Smad2/Smad3.
METHODS
Patients
Fifteen patients diagnosed as having FSGS were se-
lected for this study. Lesions of FSGS were observed
in all these patients affecting 6% to 50% [22  14%
(mean  SD)] of the glomeruli. None of these patients
had any prior history of diabetes mellitus, cyanotic heart
disease, reflux nephropathy, obesity, autoimmune dis-
ease, or drug abuse. The control specimens were ob-
tained during kidney donation for transplantation from a
35-year-old man and from five patients with microscopic
hematuria, but with no detectable abnormalities. Renal
biopsy specimens with more than 10 glomeruli were pro-
cessed in preparation for light, electron, and immuno-
fluorescence microscopy. In the case of light microscopy,
the kidney tissues were fixed overnight in 4% paraform-
aldehyde at 4C.
The patients’ ages ranged from 12 to 69 years with a
mean age of 36 20 years. The male to female ratio was
2:1. Three patients (20%) showed a sign of hypertension,
which was defined as having a blood pressure greater
than 140/90 mm Hg. Seven patients (47%) had nephrotic-
range proteinuria, with a protein excretion of 3.5 g/day
or greater at the time of the biopsy. Renal insufficiency,
defined as having a serum creatinine level greater than
1.5 mg/dL, was observed in five cases.
Immunohistochemistry
An avidin-biotin-peroxidase procedure (Dakopatts,
Glostrup, Denmark) was used for antibody localization.
Paraffin-embedded kidney sections were deparaffinized
serially. Subsequently, these sections were baked in a
microwave oven for 15 minutes. They were then incu-
bated overnight at 4C with rabbit anti-TGF-IIR (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA) and anti-
human Wilms’ tumor protein-1 (WT-1) (Santa Cruz Bio-
technologies) at a dilution of 1 in 100. To demonstrate the
presence of glomerular epithelial protein-1 (GLEPP-1),
sections were incubated with rabbit antihuman GLEPP-1
(a gift from Dr. Roger Wiggins of the University of
Michigan) at a dilution of 1 in 1000 for 11⁄2 hours at room
temperature. The sections used to demonstrate the pres-
ence of TSP-1 were treated with trypsin for 15 minutes
and then incubated overnight with goat anti-TSP-1 (Santa
Cruz Biotechnologies) at a dilution of 1 in 200. The other
sections were baked in a microwave oven for 5 minutes
and then incubated with rabbit antiphosphorylated Smad2/
Smad3 (Santa Cruz Biotechnologies) at a dilution of 1
in 1000 for 11⁄2 hours at room temperature. To demon-
strate the presence of TGF-1, deparaffinized sections
were treated with 6 mol/L acid-urea for 30 minutes and
then incubated overnight at 4C with rabbit antihuman
TGF-1 (Santa Cruz Biotechnologies) at a dilution of
1:50. Biotinylated goat antirabbit immunoglobulin or
rabbit antigoat immunoglobulin (Dakopatts) were used
as a secondary antibody. Endogenous peroxidase activity
was quenched with methanol-H2O2 solution. A strepta-
vidin-conjugated horseradish peroxidase complex incu-
bation was performed, followed by the addition of di-
aminobenzidine. The sections were counterstained with
Mayer’s hematoxylin. Control experiments were per-
formed by omitting the primary antibody or replacing it
with the corresponding nonimmune serum.
The expression and distribution patterns of WT-1,
GLEPP-1, TGF-1, TSP-1, TGF-IIR, and phosphory-
lated Smad2/Smad3 in glomeruli were assessed by three
pathologists (J.H.K., K.C.M., and H.S.L.) independently
in a blinded manner. For each glomerulus showing the
lesion of FSGS, a quantitative analysis for TGF-1,
TSP-1, TGF-IIR, and phosphorylated Smad2/Smad3
was performed. First, the total number of GEC in the
sclerotic segment and nonsclerotic area was separately
counted. Next, the number of GEC that stained positive
for each antibody was counted in both areas to obtain
the percent of podocytes that express the TGF-/Smad
signaling proteins in the sclerotic area and in the non-
sclerotic area.
Generation of digoxigenin (DIG)-labeled riboprobes
and in situ hybridization histochemistry
A 0.9 kb cDNA for rat TGF-1 [36], a 0.6 kb cDNA
for human TSP-1 [37], and a 0.5 kb cDNA for human
TGF-IIR [38] were used for this study. These cDNA
probes were obtained from the American Type Culture
Collection (Rockville, MD, USA). To amplify the cDNA
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Fig. 1. Immunoperoxidase staining for Wilms’ tumor protein-1 (WT-1)
(A and B ) and glomerular epithelial protein-1 (GLEPP-1) (C and D )
in renal biopsy sections. Healthy controls show a nuclear staining for
WT-1 in the glomerular epithelial cells (GEC) (A) and a diffuse linear
staining for GLEPP-1 along the glomerular capillary wall and the cell
membrane of the GEC (C). In the patients with focal segmental glomer-
ulosclerosis (FSGS), the staining for WT-1 (B) or GLEPP-1 (D) is lost
in the GEC (arrows) of the sclerotic lesions.
templates, a polymerase chain reaction (PCR) was
carried out using T7 and T3 promoters as primers. Two
oppositely oriented promoters served to provide two
transcripts of the same template, one of which was com-
plementary (antisense), the other being identical (sense)
to the target mRNA. DIG-labeled riboprobes were gen-
erated using an RNA labeling in vitro transcription kit
(DIG RNA Labeling Kit) (Boehringer Mannheim, Ger-
many).
In situ hybridization was performed using paraffin-
embedded renal tissues, as described in one of our previ-
ous reports [39].
RESULTS
Immunohistochemical studies
WT-1. In the controls, all podocytes expressed WT-1
in the nuclei (Fig. 1A). In the cases of FSGS, WT-1
expression was absent in the GEC covering the sclerotic
segments (Fig. 1B).
GLEPP-1. Control biopsies stained with anti-GLEPP-1
showed a diffuse linear staining along the glomerular
basement membrane and the cell membrane of the podo-
cytes (Fig. 1C). In the FSGS specimens, there was a loss
of GLEPP-1 in the GEC of the sclerotic segments (Fig.
1D). Even in the nonsclerotic glomeruli, immunostaining
for GLEPP-1 was segmentally absent.
TGF-b1. In the controls, there was no staining for
TGF-1 in the glomeruli (Fig. 2A). In the cases of FSGS,
TGF-1 was mostly negligible in the nonsclerotic glo-
meruli, except for a few isolated GEC showing TGF-1
Fig. 2. Immunoperoxidase staining for transforming growth factor-1
(TGF-1) (A and B ), thrombospondin-1 (TSP-1) (C and D ), TGF-
type II receptor (TGF-IIR) (E and F ), and phosphorylated Smad2/
Smad3 (G and H ) in renal biopsy sections. In healthy controls, there
is no staining for TGF-1 (A), TSP-1 (C), TGF-IIR (E), and phosphor-
ylated Smad2/Smad3 (G). In the cases of FSGS, prominent immuno-
staining for TGF-1 (B), TSP-1 (D), TGF-IIR (F), and phosphorylated
Smad2/Smad3 (H) is observed in the glomerular epithelial cells (GEC)
overlying the sclerotic segments. Control periodic acid-Schiff (PAS)-
stained section (I) and PAS-stained serial section showing the location
of FSGS lesion (J). (B, D, F, H and J) are serial sections.
immunoreactivity. In the FSGS lesions, moderate to
strong immunostaining for TGF- was apparent in the
GEC overlying the sclerotic segments (Table 1) (Fig. 2B).
Despite the presence of considerable sclerosis, the viable
cells within these lesions retained the ability to over-
express TGF-1. However, in the advanced sclerotic le-
sions with few viable cells, no staining was observed.
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Table 1. Expression of transforming growth factor- (TGF-)/
Smad signaling proteins in podocytes in patients with focal
segmental glomerulosclerosis (FSGS)
TGF-
Glomeruli TGF-1 TSP-1 IIR p-Smad
examined
Percent-positive podocyteNo.
FSGS (N  15) 3.31.9a
Sclerotic A 8716b 966b 8715b 993b
Nonsclerotic A 35 87 12 279
Control (N  6) 5.82.1 0 0 0 0
Abbreviations are: A, area; TSP-1, thrombospondin-1; TGF- IIR, TGF-
type II receptor; p-Smad, phosphorylated Smad2/Smad3. Data are expressed as
mean  SD.
a Glomeruli showing the lesion of FSGS
bP  0.05 vs. nonsclerotic area
TSP-1. TSP-1 was negative in the glomeruli of the
control biopsies (Fig. 2C). In the FSGS specimens, only
a few isolated GEC exhibited TSP-1 immunostaining in
the nonsclerotic glomeruli. TSP staining was distinctively
observed in the hyperplastic GEC in the cellular lesions
of FSGS (Table 1) (Fig. 2D).
TGF-bIIR. No staining for TGF-IIR was observed
in the glomeruli of the controls (Fig. 2E). In the patients
with FSGS, TGF-IIR expression was negligible in the
nonsclerotic glomeruli. In the FSGS lesions, strong
TGF-IIR immunoreactivity was observed in the GEC
overlying the sclerotic segments (Table 1) (Fig. 2F).
Phosphorylated Smad2/Smad3. In the controls, there
was no immunostaining for phosphorylated Smad2/Smad3
(Fig. 2G). In the cases of FSGS, GEC occasionally exhib-
ited positive nuclear staining for phosphorylated Smad2/
Smad3 in the nonsclerotic areas. In the cellular FSGS le-
sions, intense staining for phosphorylated Smad2/Smad3
was noted in the enlarged nuclei of the hyperplastic GEC
(Table 1) (Fig. 2H).
The location of FSGS lesion, which expressed TGF-,
TSP-1, TGF-IIR, and phophorylated Smad2/Smad3,
was demonstrated in periodic acid-Schiff (PAS)-stained
serial section (Fig. 2J) in contrast to control PAS-stained
section (Fig. 2I).
In situ hybridization studies
TGF-b1 mRNA. A weak signal for TGF-1 mRNA was
shown in several GEC and mesangial cells in the control
renal biopsies (Fig. 3A), as described previously [39]. In
most of the cases of FSGS, the number of glomerular
cells showing an enhanced signal for TGF-1 transcripts
was increased. All biopsies containing FSGS lesions ex-
hibited intense signals for TGF-1 mRNA in the GEC
of the sclerotic segments (Fig. 3B). Tubular epithelial
cells and vascular endothelial cells frequently showed
the message for the TGF- gene.
TSP-1 mRNA. In the control renal biopsies, the GEC
frequently showed a distinctive signal for TSP-1 mRNA
Fig. 3. Detection of transforming growth factor-1 (TGF-1) (A and
B ), thrombospondin-1 (TSP-1) (C, D, G, and H ), and TGF- type II
receptor (TGF-IIR) (E and F ) mRNAs in renal biopsies of healthy
controls (A, C, E, and G) and focal segmental glomerulosclerosis
(FSGS) patients (B, D, F, and H). In FSGS, renal biopsy sections
hybridized with probes specific for TGF-1 (B), TSP-1 (D), and TGF-
IIR (F) show positive signals in the glomerular epithelial cells (GEC)
of the sclerotic segments (arrows). Control in situ hybridization with
sense TSP-1 riboprobe in renal biopsies of healthy control (G) and
FSGS patient (H).
(Fig. 3C). The tubular epithelial cells and vascular en-
dothelial cells occasionally showed the message for the
TSP-1 gene. In the FSGS specimens, an intense signal
for TSP-1 mRNA was apparent in the GEC overlying
the sclerotic segments (Fig. 3D). In the nonsclerotic glo-
meruli, the number of GEC showing a signal for TSP-1
transcripts was not significantly different from that of
the controls.
TGF-bIIR mRNA. In the control renal biopsies, a dis-
tinctive signal for TGF-IIR mRNA was observed in
several glomerular cells (Fig. 3E). Tubular epithelial cells
and vascular endothelial cells also occasionally showed
the message for the TGF-IIR gene. In the cases of FSGS,
a strong signal for TGF-IIR mRNA was apparent in
the hyperplastic GEC overlying the sclerotic segments
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(Fig. 3F). In the nonsclerotic glomeruli, the number of glo-
merular cells showing an enhanced signal for TGF-IIR
transcripts was significantly increased as compared with
the controls.
No hybridization was observed in the sections probed
with the sense riboprobes for TGF-1, TGF-IIR, and
TSP-1 (Fig. 3 G and H).
DISCUSSION
This study demonstrates, to the best of our knowledge
for the first time, that the expression of the key compo-
nents of the TGF- system, including TGF-1, TSP-1,
TGF-IIR, and phosphorylated Smad2/Smad3, is in-
creased in the GEC in the FSGS lesions, wherein WT-1
and GLEPP-1 are not generally detected. These results
support the hypothesis that the activation of the TGF-/
Smad signaling cascade in damaged podocytes plays an
important role in the pathogenesis of FSGS.
In our patients with FSGS, the expression of TGF-1
mRNA and protein was markedly increased in the GEC
of the FSGS lesions. However, immunoreactivity for
TGF-1 in the nonsclerotic glomeruli was mostly negligi-
ble, despite the increased expression of its mRNA. These
findings are similar to those described in the cellular
lesions of FSGS, in patients with IgA nephropathy [14],
suggesting that the induction of TGF-1 synthesis in
GEC could represent a common pathway mediating glo-
merulosclerosis, regardless of the underlying disease. In
partial agreement with our observations, Yamamoto et al
[13] reported a segmental intraglomerular staining for
TGF-1, associated with the matrix, in the case of FSGS.
We also found that TSP-1 protein and mRNA were
overexpressed in the cellular lesions of FSGS. Increased
TSP-1 expression has been observed in human glomerul-
opathies associated with early fibrosis [22]. TSP-1 was
also particularly prominent in the sclerotic lesions in the
remnant kidney model [40], while it was only transiently
expressed in the proliferating mesangial cells in the anti-
Thy-1.1 nephritis model [41].
TGF- is usually secreted as a latent complex, and
TSP-1 is known to be a major physiologic activator of
latent TGF- [19]. Thus, our demonstration of increased
expression of both TSP-1 and TGF-, in the GEC of the
FSGS lesions, suggests that TSP-1 may activate latent
TGF- secreted by GEC. However, the existence of other
mechanisms of TGF- activation, during the develop-
ment of FSGS, cannot be excluded. Of the various pro-
teolytic factors known to activate latent TGF- in vitro,
plasmin [42–44] or reactive oxygen species [45] could
function as an in vivo activator of TGF-. Latent TGF-
can also be activated via binding to the v6 integrin in
vivo [46]. Epithelial cells express this particular integrin
[47] and, therefore, the above mechanism may also oper-
ate on the activation of TGF- secreted by GEC.
In our patients with FSGS, expression of TGF-IIR
mRNA and protein was also markedly increased in the
GEC of the FSGS lesions. In accordance with our find-
ings, Yamamoto et al [33] also observed increased immu-
nostaining for TGF- receptors in the GEC close to the
glomerulosclerotic lesions. TGF-IIR protein also stained
more abundantly in the glomeruli of the db/db mice than
the controls, particularly in the podocytes [34]. Increased
TGF-IIR expression may allow the podocytes to re-
spond more actively to TGF-, thus leading to the ac-
tivation of the TGF- type I receptor and the Smad
pathways.
In the present study, prominent nuclear staining for
phosphorylated Smad2/Smad3 was observed in the GEC
covering the sclerotic segments. Although diffuse cyto-
plasmic and nuclear staining for Smad3 has been de-
scribed in the glomeruli of db/db mice [35], this is the
first study that demonstrates that the phosphorylated
Smads translocated into the nuclei of the GEC in the
case of FSGS. The phosphorylated Smads associated with
Smad4, which translocated into the nucleus, could acti-
vate specific TGF-1 target genes, including the ECM
component plasminogen activator inhibitor-1, type I col-
lagen, fibronectin, and TGF-1 itself [30, 48–51]. Thus,
the overproduction of TGF-1 protein, and the activation
of its downstream signaling in GEC, could lead to con-
tinued matrix protein synthesis, resulting in segmental
thickening of the glomerular basement membrane. This
process may ultimately lead to the segmental collapse
of the glomerular capillary tuft and thus to the develop-
ment of scarring [52, 53].
Podocyte injury is the first event to occur in the natural
progression of FSGS [3, 4], resulting in the loss of dif-
ferentiation markers of podocytes [7, 9]. In rats with
reduced renal mass, dedifferentiation and injury of podo-
cytes occurred as a consequence of increased transcapil-
lary passage, and this process seems to be associated with
an increased level of TGF-1 expression in podocytes
[54]. We also observed the disappearance of the podo-
cyte-specific markers, WT-1 and GLEPP-1, in the GEC
of FSGS lesions, corroborating the hypothesis that dam-
aged GEC can initiate a cascade of TGF- signaling.
Earlier studies showed that TGF-1 stimulated the
expression of type IV collagen and fibronectin in cul-
tured GEC [55]. A recent report demonstrated that
TGF-1 decreased 1(IV) and 5(IV) collagen expres-
sion in a mouse podocyte cell line, whereas it increased
3(IV) collagen expression [34]. The selective analysis
of podocytes in vitro was difficult, because only incom-
pletely differentiated podocytes, of questionable cellular
origin, were used in most culture studies performed to
date [56–59]. Thus, the discordant results on TGF-1–
induced type IV collagen expression obtained in cul-
tured GEC or the podocyte cell line should be inter-
preted with caution.
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CONCLUSION
We demonstrated the increased expression of TGF-1,
TSP-1, TGF-IIR, and phosphorylated Smad2/Smad3 in
the GEC in FSGS lesions, wherein WT-1 and GLEPP-1
were not detected. These results suggest that damage to
podocytes may stimulate a signal transduction cascade
of the TGF-/Smad signaling pathway, leading to the
overproduction of ECM. Thus, the TGF-/Smad signal-
ing pathway, which is activated in the GEC, appears to
be involved in the development of FSGS.
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